Ocuphire Pharma Results

Why DRSS is an Important Endpoint? FDA Accepted Endpoint for EYLEAⓇ in PANORAMA Pivotal DR Trial - 2 Step Improvement on the DRSS Score Diabetic Retinopathy Severity Scale (DRSS) ► INCREASING RISK OF DEVELOPING VISION THREATENING COMPLICATIONS ► DRSS 35 Mild NPDR • Visual symptoms mostly absent • Small bulges in blood vessels and intraretinal hemorrhages ■ Ocuphire Eylea® Panorama study PHARMA DRSS 43 Moderate NPDR • May experience visual symptoms Spotted leaking of blood ● ¯¯¯¯¯¯¯¯¯¯¯ DRSS 47 Moderately Severe NPDR • May experience visual symptoms • Leaking of blood in retina, unevenly shaped veins Example of 2-step improvement DRSS 53 Severe NPDR • May experience visual symptoms Widespread leaking of blood, more unevenly shaped veins DRSS > 60 PDR • Visual symptoms are usually present • Growth of new fragile blood vessels, in some cases leading to bleeding in the retina and center of the eye ■ 43

View entire presentation